espite the devastating impact that mood disorders have on the lives of millions worldwide, there is still a dearth of knowledge concerning their underlying etiology and pathophysiology. The brain systems that have heretofore received the greatest attention in neurobiological studies of major depressive disorder (MDD) are the monoaminergic neurotransmitter systems, which are extensively distributed throughout the network of limbic, striatal, and prefrontal cortical neuronal circuits thought to support the behavioral and visceral manifestations of mood disorders.
There is mounting evidence that recurrent mood disorders-once considered "good prognosis diseases"-are, in fact, often very severe and life-threatening illnesses. Furthermore, although mood disorders have traditionally been conceptualized as neurochemical disorders, there is now evidence from a variety of sources demonstrating regional reductions in central nervous system (CNS) volume, as well as reductions in the numbers and/or sizes of glia and neurons in discrete brain areas. Although the precise cellular mechanisms underlying these morphometric changes remain to be fully elucidated, the data suggest that mood disorders are associated with impairments of synaptic plasticity and cellular resilience. In this context, it is noteworthy that there is increasing preclinical evidence that antidepressants regulate the function of the glutamatergic system. Moreover, although clearly preliminary, the available clinical data suggest that attenuation of N-methyl-D-aspartate (NMDA) function has antidepressant effects. Recent preclinical and clinical studies have shown that signaling pathways involved in regulating cell survival and cell death are long-term targets for the actions of antidepressant agents. Antidepressants and mood stabilizers indirectly regulate a number of factors involved in cell survival pathways, including cyclic adenosine monophosphate (cAMP) response element binding protein (CREB), brain-derived neurotrophic factor (BDNF), the antiapoptotic protein bcl-2, and mitogen-activated protein (MAP) kinases, and may thus bring about some of their delayed long-term beneficial effects via underappreciated neurotrophic effects.
There is much promise for the future development of treatments that more directly target molecules in critical CNS signaling pathways regulating synaptic plasticity and cellular resilience. These will represent improved long-term treatments for mood disorders.
second-generation medications (eg, serotonin-selective reuptake inhibitors [SSRIs] and norepinephrine-selective reuptake inhibitors), which are widely used today. Thus, clinical studies over the past 40 years have attempted to uncover the specific defects in these neurotransmitter systems in mood disorders by utilizing a variety of biochemical and neuroendocrine strategies. Indeed, assessments of cerebrospinal fluid (CSF) chemistry, neuroendocrine responses to pharmacological challenge, and neuroreceptor and transporter binding have, in fact, demonstrated a number of abnormalities of the serotonergic, noradrenergic, and other neurotransmitter and neuropeptide systems in MDD. While such investigations have been heuristic over the years, they have been of limited value in elucidating the unique neurobiology of mood disorders. Furthermore, while most antidepressants exert their initial biochemical effects by increasing the intrasynaptic concentrations of serotonin and/or norepinephrine, their clinical antidepressant effects are only observed after chronic administration (days to weeks), suggesting that a cascade of downstream effects are ultimately responsible for their therapeutic effects. These observations have led to the appreciation that, while dysfunction within the monoaminergic neurotransmitter systems is likely to play important roles in mediating some facets of the pathophysiology of mood disorders, these disorders likely represent the downstream effects of other more primary abnormalities. In addition to the growing appreciation that investigations into the pathophysiology of mood disorders have been excessively focused on monoaminergic systems, it is increasingly being recognized that progress in developing truly novel and improved antidepressant medications has consequently also been limited. The SSRIs, for example, have a better side-effect profile for many patients, and are easier for physicians to prescribe. However, these newer medications have essentially the same mechanism of action as the tricyclic antidepressants and, as a result, the efficacy of the newer agents and the range of depressed patients they treat are no better than the older medications. Moreover, today's treatments remain suboptimal for many patients afflicted with depressive syndromes. A recognition of the lack of significant advances in our ability to develop novel, improved therapeutic agents for these devastating illnesses has led to the investigation of the putative roles of intracellular signaling cascades in the pathophysiology and treatment of mood disorders. Multicomponent, cellular signaling pathways interact at various levels, thereby forming complex signaling networks, which allow neurons to receive, process, and respond to information, and to modulate the signal generated by multiple different neurotransmitter and neuropeptide systems. 3, 4 This is noteworthy since mood disorders undoubtedly arise from a complex interaction of multiple susceptibility (and likely protective) genes and environmental factors, and the phenotypic expression of these diseases includes not only episodic and often profound mood disturbance, but also a constellation of cognitive, motoric, autonomic, endocrine, and sleep/wake abnormalities. Thus, intracellular signaling cascades are critically involved in regulating complex psychological and cognitive processes, as well as diverse neurovegetative functions, such as appetite and wakefulness. Consequently, recent evidence that impairments of neuroplasticity and cellular resilience underlie the pathophysiology of MDD, and that antidepressants and mood stabilizers exert major effects on the signaling pathways that regulate neuroplasticity and cell survival, has generated considerable excitement among the clinical neuroscience community, and is reshaping views about the neurobiological underpinnings of these disorders. "Neuroplasticity" subsumes diverse processes of vital importance by which the brain perceives, adapts to, and C l i n i c a l r e s e a r c h ). Although the potential relevance of neuroplastic events to the pathophysiology of psychiatric disorders has been articulated for some time, 6 recent morphometric studies of the brain (both in vivo and postmortem) are beginning to lead to a fuller appreciation of the magnitude and nature of the neuroplastic events involved in the pathophysiology of mood disorders. [7] [8] [9] In this perspectives paper, we review these data and discuss their implications not only for changing existing conceptualizations regarding the pathophysiology of MDD, but also for the strategic development of improved therapeutic agents.
Evidence for impairments of structural plasticity and cellular resilience in mood disorders
Positron emission tomography (PET) imaging studies have revealed multiple abnormalities of regional cerebral blood flow (CBF) and glucose metabolism in limbic and prefrontal cortex (PFC) structures in mood disorders. These abnormalities implicate limbic-thalamic-cortical and limbic-cortical-striatal-pallidal-thalamic circuits, involving the amygdala, orbital, and medial PFC, and anatomically related parts of the striatum and thalamus in the pathophysiology of mood disorders. Interestingly, recent morphometric magnetic resonance imaging (MRI) and postmortem investigations have also demonstrated abnormalities of brain structure that persist independently of mood state and may contribute to the corresponding abnormalities of metabolic activity (discussed in references 2 and 10). Thus, structural imaging studies have demonstrated reduced gray matter volumes in areas of the orbital and medial PFC, ventral striatum, and hippocampus, and enlargement of the third ventricle in mood-disordered samples relative to healthy control samples (Table I) . Complementary postmortem neuropathological studies have shown abnormal reductions in cortex volume, glial cell counts, and/or neuron size in the subgenual PFC, orbital cortex, dorsal anterolateral PFC, and amygdala (Table II) . 8, [78] [79] [80] [81] [82] [83] [84] It is not currently known whether these deficits constitute developmental abnormalities that may confer vulnerability to abnormal mood episodes, compensatory changes to other pathogenic processes, or the sequelae of recurrent affective episodes per se. Understanding these issues will partly depend upon experiments that delineate the onset of such abnormalities within the illness course and determine whether they antedate depressive episodes in individuals at high familial risk for mood disorders. Nevertheless, the marked reduction in glial cells in these regions has been particularly intriguing in view of the growing appreciation that glia play critical roles in regulating synaptic glutamate concentrations and CNS energy homeostasis, and in releasing trophic factors that participate in the development and maintenance of synaptic networks formed by neuronal and glial processes. 80, 81, [85] [86] [87] [88] Abnormalities in glial function could thus prove integral to the impairments of structural plasticity and overall pathophysiology of mood disorders.
Stress and glucocorticoids modulate neural plasticity: implications for mood disorders
In developing hypotheses regarding the pathogenesis of these histopathological changes in MDD, the alterations in cellular morphology resulting from various stressors have been the focus of considerable recent research. Thus, although MDD undoubtedly has a strong genetic basis, considerable evidence has shown that severe stressors are associated with a substantial increase in risk for the onset of mood disorders in susceptible individuals. In rodents, certain stressors are capable of producing dendritic atrophy, death, or endangerment (priming the substrate so that it is more vulnerable to other pathophysiological insults) of hippocampal CA3 pyramidal neurons. [89] [90] [91] The extent to which such stress-induced neuronal changes also occur in other brain regions remains unclear. Activation of the hypothalamic-pituitary-adrenal (HPA) axis appears to play a critical role in mediating these effects, since stress-induced neuronal atrophy is prevented by adrenalectomy, and duplicated by exposure to high concentrations of glucocorticoids (reviewed in references 89 to 91). These observations are noteworthy with respect to the pathophysiology of mood disorders, since a significant percentage of patients with MDD display some form of HPA axis activation, and the subtypes of depression most frequently associated with HPA axis activation are those most likely to be associated with hippocampal volume reductions. 90 A significant percent- Altshuler et al, 1991 11 Andreasen et al, 1990 12 Ali et al, 2001 13 Ashtari et al, 1999 14 Bakshi et al, 2000 15 Baumann et al, 1997 16 Beats et al, 1991 17 Brambilla et al, 2001 18 Brambilla et al, 2001 19 Bremner et al, 2000 20 Coffey et al, 1993 21 Coffman et al, 1990 22 Dahabra et al, 1998 23 Dasari et al, 1999 24 DelBello et al, 1999 25 Dewan et al, 1988 26 Dolan et al, 1986 27 Drevets et al, 1997 28 Friedman et al, 1999 29 50 Rabins et al, 1991 51 Rabins et al, 2000 52 Roy et al, 1998 53 Sassi et al, 2001 54 Sax et al, 1999 55 Schlegel and Kretzschmar, 1987 56 Shah et al, 1992 57 Shah et al, 1998 58 Sheline et al, 1996 59 Sheline et al, 1998 60 Sheline et al, 1999 61 Shima et al, 1984 62 Shiraishi et al, 1992 63 Simpson et al, 1999 64 Simpson et al, 2001 65 Steffens et al, 2000 66 Strakowski et al, 1993 67 Strakowski et al, 1999 68 Swayze et al, 1990 69 Swayze et al, 1992 70 Tanaka et al, 1982 71 Vakili et al, 2000 72 Velakoulis et al, 1999 73 Weinberger et al, 1982 74 Wurthmann et al, 1995 75 Young et al, 1999 76 Zipursky et al, 1997 77 age of patients with Cushing's disease, in which pituitary gland adenomas result in cortisol hypersecretion, are also known to manifest prominent depressive symptoms, as well as hippocampal atrophy. Furthermore, some patients with Cushing's disease show a reduction in hippocampal volume that correlates inversely with plasma cortisol concentrations; following corrective surgical treatment, enlargement of hippocampal volume is observed in proportion to the treatment-associated decrement in urinary free cortisol concentrations. 92, 93 In addition to directly causing neuronal atrophy, stress and glucocorticoids also appear to reduce cellular resilience, thereby making certain neurons more vulnerable to other insults, such as ischemia, hypoglycemia, and excitatory amino acid toxicity. 90 Thus, recurrent stress (and presumably recurrent MDD episodes, which are often associated with hypercortisolemia) may lower the threshold for cellular death/atrophy in response to a variety of physiological (eg, aging) and pathological events. Such processes may conceivably also play a role in the relationship between mood disorders and cerebrovascular events, considering that individuals who develop their first depressive episode in late life have an increased likelihood of showing MRI evidence of cerebrovascular disease. 39, [94] [95] [96] [97] [98] The precise mechanisms by which glucocorticoids exert these deleterious effects on the hippocampus remain to be fully elucidated, but likely involve the inhibition of glucose transport (thereby diminishing capability of energy production, leading to a cellular failure to handle increasing "loads"), and the facilitation of glutamatergic signaling. 90 The latter observation is noteworthy since, as we discuss below, there is increasing evidence for an association between alterations of brain glutamatergic neurotransmission and the pathophysiology of mood disorders. (used as a part of multidrug antituberculosis treatment) was reported to have mood-elevating effects. 99 The beneficial effects of D-cycloserine at doses of 500 mg/day occurred in a high proportion of the patient studies with respect to depressed mood, insomnia, and reduced appetite (as discussed in reference 100). Although D-cycloserine clearly exerts multiple pharmacologic effects at the doses employed to treat tuberculosis, it has mild acute, dose-related euphoric and amnesic effects in humans that resemble the effects of subperceptual doses of noncompetitive NMDA antagonists. 100 Thus, it has been suggested that the antidepressant effects of D-cycloserine may reflect consequences of its capacity to reduce NMDA receptor function. 100 Since these early serendipitous clinical observations, a growing body of preclinical and clinical research suggests that the NMDA class of glutamate receptors may be involved in the pathophysiology of MDD and the mechanism of action of antidepressants (Table III) . NMDA receptor antagonists such as dizocilpine and AP-7 (2-amino-7-phosphonoheptanoic acid), and an α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptor potentiator, the biarylpropylsulfonamide LY392098, have demonstrated antidepressant effects in animal models of depression (including the application of inescapable stressors, forced-swim, and tail suspension-induced immobility tests), in learned-helplessness models of depression, and in animals exposed to a chronic mild stress procedure (reviewed in references 100 and 121). In some of these studies, NMDA receptor antagonists had dose-related effects that were comparable in magnitude, but more rapid, than imipramine. Moreover, chronic administration of "conventional" antidepressants has been shown to affect NMDA receptor function 100, 121, 123 and NMDA receptor-binding profiles, and to regionally alter expression of mRNA that encode multiple NMDA receptor subunits. 100, 121, [123] [124] [125] Recently, Berman et al 109 reported the first placebo-controlled, double-blind trial assessing the treatment effects of a single dose of an NMDA receptor antagonist, ketamine, in 7 patients with depression. The ketamine infusion produced mild psychosis and euphoria that dissipated within 120 min. In contrast, the antidepressant effects of ketamine infusion emerged over the first 180 min and persisted over 72 h. Within this intriguing study, some patients reported antidepressant effects lasting as long as a week. 100, 109 Similarly, several case reports and open studies have reported the efficacy of lamotrigine (which among other effects, robustly reduces glutamate release) in bipolar depression. A randomized, placebocontrolled, 7-week study comparing two doses of lamotrigine with placebo in 195 patients with moderate-tosevere bipolar depression has now been completed. Lamotrigine was superior to placebo after 3 weeks as assessed by changes on the Montgomery-Åsberg Depression Rating Scale (MADRS). 108 Overall, the data suggest that regionally selective abnormally enhanced glutamatergic functioning-either primary or secondary to enhanced glucocorticoid releasemay contribute to the impairment of neuroplasticity and cellular resilience observed in mood disorders. More importantly for the present discussion, although quite preliminary, the existing data suggest that medications that attenuate glutamatergic functioning (and perhaps more specifically, NMDA throughput) may possess antidepressant effects. 100, 121 Ongoing studies investigating the putative antidepressant effects of riluzole (which reduces glutamate release) and memantine (an NMDA antagonist) may ultimately lead to the development of novel antidepressant strategies targeting the glutamatergic system.
The role of the neurotrophic signaling cascades in the pathophysiology and treatment of mood disorders
The reduction in neuroplasticity and cellular resilience may also reflect the propensity for various stressors (and potentially mood disorders) to decrease the expression of neurotrophic factors. [7] [8] [9] 126, 127 Neurotrophins are a family of regulatory factors that mediate the differentiation and survival of neurons, as well as the modulation of synaptic transmission and synaptic plasticity. Neurotrophins can be secreted constitutively or transiently, and often in an activity-dependent manner. 127 Recent observations support a model wherein neurotrophins are secreted from the dendrite and act in a retrograde manner at presynaptic terminals, where they act to induce long-lasting modifications. Within the neurotrophin family, brainderived neurotrophic factor (BDNF) is a potent physiological survival factor, which has also been implicated in a variety of pathophysiological conditions, such as Parkinson's disease, Alzheimer's disease, and diabetic peripheral neuropathy. 127 BDNF and other neurotrophic factors are necessary for the survival and function of neurons, 128 implying that a sustained reduction of these factors could affect neuronal viability. Although endoge- 103 Plasma and platelet levels of glu Increased plasma and decreased platelet level in medicationfree depressed patients (4 MDD, 11 BP) versus controls Altamura et al, 1995 104 Plasma levels of gly, glu Lower in 25 medication-free MDD patients than controls Nowak et al, 1995 105 High 106 Plasma and platelet levels of glu, asp, Higher glu plasma level and asp platelet level in 29 MDD patients and other aa than controls, not altered by fluvoxamine Maes et al, 1998 107 Plasma levels of asp and other aa No differences between patients and control. Lower asp level in MDD patients who were nonresponders to antidepressant treatment for 5 weeks. Treatment reduced levels of asp and glu, and increased gln Calabrese et al, 1999 108 Antidepressant response to lamotrigine Significant antidepressant efficacy in 195 depressed BPI patients (double-blind, placebo-controlled study) Berman et al, 2000 109 Antidepressant response to ketamine Improvement of symptoms in depressed patients (8 MDD, 1 BP) (double-blind, placebo-controlled study) lasted longer (3 days) than euphoric effects (hours) Castillo et al, 1999 110 glu/gln ratio measured by MRS Elevated in frontal lobe and basal ganglia in BP medication-free children vs controls in FC, temporal cortex, and basal ganglia Auer et al, 2000 111 Levels of glu measured by MRS Decreased in anterior cingulate cortex of depressed patients (1 BP, 18 MDD) vs controls (7 patients were medication-free and 12 on antidepressants) Levine et al, 2000 112 CSF gln levels Elevated in medication-free depressed patients vs control (2 BP, 16 MDD) and correlated with CSF Mg level Berk et al, 2001 113 Platelet intracellular calcium Greater in 15 MDD medication-free patients than controls response to glu stimulation Meador-Woodruff NMDA mRNA subunit levels Postmortem brain analysis. Only NR2D (a subunit of the et al, 2001 114 in striatum NMDA receptor) mRNA is higher in BP (15) vs MDD (15) . Only gluR1 (a subunit of the AMPA receptor) mRNA is lower in BP vs controls (15 118 Chronic administration (16 days) of citalopram in mouse lowered NMDA ε1-subunit mRNA level in FC, CA2 of hippocampus, and amygdala, whereas imipramine only does so in amydgala. Imipramine lowered NMDA ε2-subunit mRNA level in cortex, CA1-4 of hippocampus, and amygdala, whereas citalopram only does so in amygdala. Both drugs reduce transcript levels of ζ-subunit in cortex, thalamus, striatum, and cerebellum Bouron and Chatton, 1999 119 Desipramine enhanced spontaneous vesicular release of glu in hippocampal neurons dissociated from neonatal rats Michael-Titus et al, 2000 120 Imipramine and phenelzine decreased stimulated (K-induced) glu outflow in rat PFC and not in striatum Chen et al, 2001 121 Ketamine pretreatment attenuated ECS-induced mossy fiber sprouting in dentate gyrus and BDNF expression in medial PFC and the dentate gyrus in rats Li et al, 2001 122 AMPA receptor potentiator LY392098 (a biarylpropylsulfonamide) produced antidepressant-like effect in rats and mice nous neurotrophic factors have traditionally been viewed as increasing cell survival by providing necessary trophic support, it is now clear that their survival-promoting effects are mediated in large part by an inhibition of cell death cascades. 129 Increasing evidence suggests that neurotrophic factors inhibit cell death cascades by activating the mitogen-activated protein (MAP) kinase signaling pathway and the phosphotidylinositol-3 kinase (PI-3K)/Akt pathway (Figure 1) . 130 One important mechanism by which the MAP kinase signaling cascades inhibits cell death is by increasing the expression of the antiapoptotic protein bcl-2. 131, 132 The neurotrophic factor/MAP kinase/bcl-2 signaling cascade may thus play a critical role in cell survival in the CNS, since there is a very fine balance maintained between the levels and activities of pro-and antiapoptotic factors; modest changes in this signaling cascade or in the levels of the bcl-2 family of proteins (potentially due to genetic, or illness-or insult-related factors) may therefore profoundly affect cellular viability. 133, 134 In addition to regulating synaptic efficacy, BDNF appears to function as a modulator that is required for the induction, expression, and/or maintenance of LTP. Thus, genetic deletion of BDNF in mice disrupts normal induction of LTP, which can be rescued by reintroducing BDNF either by transfecting hippocampal slices with BDNF-expressing adenovirus or the exogenous administration of BDNF. 127 The information reviewed here clearly shows that neurotrophin signaling cascades play a major role in regulating various forms of neuronal and synaptic plasticity, as well as neuronal survival-all of which may be impaired in severe recurrent mood disorders. We now turn to a discussion of the evidence that neurotrophic signaling cascades are long-term targets for antidepressants and mood stabilizers.
Influence of antidepressant treatment on cell survival pathways
In an extensive series of studies, Duman and associates have demonstrated that the cyclic adenosine monophosphate (cAMP)-cAMP response element binding protein (CREB) cascade-an important pathway involved in cell survival and plasticity-is upregulated by chronic antidepressant treatment, in a timeframe that parallels clinical response. 7, [135] [136] [137] [138] The results include increased coupling of the stimulatory G-protein, Gs, to adenylyl cyclase, increased protein kinase A (PKA) activity in the particulate fraction of limbic structures, increased PKA levels in the nuclear fractions of cerebral cortex, and increased mRNA expression of the type 1 adenylyl cyclase in the rat hippocampus. 7, 135 The same workers have found that chronic administration of different classes of antidepressants-SSRIs (fluoxetine and sertraline), a selective norepinephrine reuptake inhibitor (desipramine), a dual aminergic reuptake inhibitor (imipramine)-and chronic electroconvulsive seizures upregulate the expression of CREB. 7, 135 By contrast, the nonantidepressant psychotropic drugs cocaine and haloperidol, did not influence CREB mRNA expression indicating the specificity of CREB induction to antidepressants. Chronic administration of these antidepressants has also been demonstrated to increase mRNA and protein levels of the cAMP-specific phosphodiesterase PDE4 isozymes, PDE4A and PDE4B, in rat frontal cortex (FC) and hippocampus. [7] [8] [9] [10] 135 The upregulation of PDE4 gene expression in response to sustained activation of the cAMP-CREB cascade likely represents a compensatory adaptation that would reduce cAMP levels back to baseline. As we discuss below, inhibition of specific phosphodiesterases may thus represent a new strategy for developing novel agents for the treatment of depression. One way in which CREB can mediate antidepressantinduced neural plasticity is by regulating target genes that are essential for maintaining synaptic function and cell survival, most notably BDNF. [7] [8] [9] [10] 135 Several studies have shown that chronic administration of different types of antidepressant increases the expression of BDNF in limbic brain areas, particularly the hippocampus, and blocks the stress-induced downregulation of BDNF in the hippocampus. [7] [8] [9] [10] 135 The possibility that increased expression of BDNF may contribute to the therapeutic effects of antidepressants is supported by the rodent behavioral studies in which direct infusion of BDNF into the rat midbrain showed efficacy in the learned-helplessness and forced-swim "depression behavioral models." [7] [8] [9] [10] 135 Although the human postmortem studies are quite limited and subject to numerous methodological confounds, they have revealed increased BDNF levels in hippocampal regions in subjects treated with antidepressant medications at the time of death, compared with unmedicated subjects. 139 As discussed above, BDNF is known to play a major role in regulating structural plasticity. Do antidepressants, via effects on this major growth factor, actually bring about structural changes in the brain? Because the dendrite is the dynamic compartment of neuronal cell body processes that forms synapses with other neurons, these changes in its spine density could dramatically alter neurotransmission, synaptic function, and ultimately, neural plasticity. [7] [8] [9] [10] 135 In this context, an important study demonstrated that chronic administration of tianeptine (an antidepressant that facilitates serotonin reuptake) blocked stress-induced dendritic remodeling of hippocampal CA3 pyramidal neurons. 139 However, precluding the generalizability to all antidepressants is the observation that chronic fluoxetine and fluvoxamine treatment (more traditional antidepressants that inhibit serotonin reuptake) had no influence on dendritic orders. Genetic/neurodevelopmental factors, repeated affective episodes, and illness progression may all contribute to the impairments of cellular resilience, volumetric reductions, and cell death/atrophy observed in mood disorders. Stress and depression likely contribute to impairments of cellular resilience by a variety of mechanisms, including reductions in the levels of brain-derived neurotrophic factor (BDNF), facilitating glutamatergic transmission via N-methyl-D-aspartate (NMDA) and non-NMDA receptors, and reducing the cell's energy capacity. Neurotrophic factors such as BDNF enhance cell survival by activating two distinct signaling pathways: the phosphotidylinositol-3 (PI-3) kinase pathway, and the extracellular signal-regulated kinase (ERK) mitogen-activated protein (MAP) kinase pathway. One of the major mechanisms by which BDNF promotes cell survival is by increasing the expression of the major cytoprotective protein, bcl-2. Bcl-2 attenuates cell death via a variety of mechanisms, including impairing the release of calcium and cytochrome C, and by sequestering proforms of death-driving cysteine proteases (called caspases), and by enhancing mitochondrial calcium uptake. The chronic administration of a variety of antidepressants increases the expression of BDNF, and its receptor trkB. Lithium and valproic acid (VPA) robustly upregulate the cytoprotective protein bcl-2. Lithium and VPA also inhibit glucogen synthase kinase (GSK-3β), biochemical effects shown to have neuroprotective effects. VPA also activates the ERK MAP kinase pathway, effects which may play a major role in neurotrophic effects and neurite outgrowth. trkB, tyrosine kinase receptor for BDNF; NGF, nerve growth factor; Bcl-2 and Bcl-x, antiapoptotic members of the bcl-2 family; BAD and Bax, proapoptotic members of the bcl-2 family; Ras, Raf, MEK, ERK, components of the ERK MAP kinase pathway; CREB, cyclic adenosine monophosphate (cAMP) response element binding protein; Rsk-2, ribosomal S-6 kinase; ROS, reactive oxygen species; GR, glucocorticoid receptor; 5-HT, 5-hydroxytryptamine (serotonin); NE, norepinephrine; GTP, guanine triphosphate; Akt, a serine-threonine kinase member of the phosphatidyl-3 kinase pathway.
remodeling. 140 More recently, the influence of chronic antidepressant treatment on neurogenesis of hippocampal neurons has been examined. 7, 135 Chronic, but not acute, antidepressant treatment was found to increase the number of new cells in the dentate gyrus granule cell layer. Furthermore, these effects were observed with different classes of antidepressants, but not with several other psychotropic medications investigated. 7, 135 A very recent detailed study investigated the effects of tianeptine in the chronic psychosocial stress model of depression in adult male tree shrews. 141 Animals were subjected to a 7-day period of psychosocial stress to elicit stressinduced endocrine and CNS alterations before the onset of daily oral administration of tianeptine (50 mg/kg). The psychosocial stress continued throughout the treatment period of 28 days. The proliferation rate of the granule precursor cells in the dentate gyrus was reduced (-33%) by stress, effects that were prevented by the simultaneous administration of tianeptine yielding normal values. In stressed animals treated with tianeptine, hippocampal volume increased above the small decrease produced by stress alone. While these effects of tianeptine are intriguing indeed, a detailed study using several different classes of antidepressants is clearly needed to determine the precise influence of antidepressants on dendritic remodeling and synaptic function. In toto, although some of the evidence is correlational rather than clearly causal, the evidence indicates that BDNF is associated with an antidepressant response and its induction may represent a key strategy for developing novel antidepressant medication. In this context, a subtle mechanism to facilitate antidepressant-induced increase in CREB/BDNF expression/function may be by the use of cAMP-specific PDE4 inhibitors. Indeed, the possibility that inhibitors of this enzyme have antidepressant efficacy is supported by older studies with rolipram, a relatively selective inhibitor of PDE4. Rolipram is reported to have efficacy in clinical trials and in preclinical models of depression, but it also produces intolerable nausea. 7 Molecular cloning studies demonstrate that there are four separate PDE4 genes, three of which are expressed in brain (PDE4A, PDE4B, and PDE4D). Current evidence suggests that PDE4A and PDE4B may be relevant targets for development of selective inhibitors. [7] [8] [9] [10] Studies are currently underway in PDE4A, PDE4B, and PDE4D null mutant mice, as well as with more selective inhibitors, to further validate these PDE4 isozymes as targets of antidepressant treatments. [7] [8] [9] [10] Mood stabilizers regulate the MAP kinase signaling cascade
As discussed above, several endogenous growth factors-including nerve growth factor (NGF) and BDNF-exert many of their neurotrophic effects via the MAP kinase signaling cascade. In view of the important role of MAP kinases in mediating long-term neuroplastic events, it is noteworthy that lithium and valproic acid (VPA), at therapeutically relevant concentrations, have recently been demonstrated to robustly activate the extracellular signal-regulated kinase (ERK) MAP kinase cascade in rat FC and hippocampus, as well as in human neuroblastoma SH-SY5Y cells (Figure 1) . 39, 52, 127, 142 Since the ERK MAP kinases are known to mediate many of the effects of various neurotrophic factors and to promote neurite outgrowth, 132, 143 VPA's effects on the morphology of human neuroblastoma cells have been examined in detail. Human neuroblastoma SH-SY5Y cells exposed to VPA (1.0 mM) in serum-free media for 5 days exhibited prominent growth cones and dramatic neurite outgrowth. Growth cone-associated protein-43 (GAP-43) is a protein expressed at elevated levels during neurite growth during development or regeneration, and a >3-fold increase in GAP-43 levels was observed after 5 days' VPA exposure. 127, 142 Follow-up studies have recently shown that, similar to the effects observed in neuroblastoma cells in vitro, chronic lithium or VPA also robustly increases the levels of activated ERK in areas of brain that have been implicated in the pathophysiology and treatment of BD: the FC and hippocampus. 142 Interestingly, neurotrophic factors are now known to promote cell survival by activating MAP kinases to suppress intrinsic, cellular apoptotic machinery, not by inducing cell survival pathways (see above). 129, [131] [132] [133] [134] [144] [145] [146] Thus, a downstream target of the MAP kinase cascade, ribosomal S-6 kinase (Rsk) phosphorylates CREB and this leads to induction of bcl-2 gene expression (Figure 1 ). Recent studies have therefore undertaken to determine if lithium or VPA regulates the expression of bcl-2. Chronic treatment of rats with "therapeutic" doses of lithium and VPA produced a doubling of bcl-2 levels in FC, effects that were primarily due to a marked increase in the number of bcl-2 immunoreactive cells in layers II and III of FC. [147] [148] [149] Interestingly, the importance of neurons in layers II to IV of the FC in mood disorders has recently been emphasized, since primate studies indicate that these areas are important for providing connections with other cortical regions, and that they are targets for subcortical input.
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Chronic lithium also markedly increased the number of bcl-2 immunoreactive cells in the dentate gyrus and striatum 144 ; and detailed immunohistochemical studies following chronic VPA treatment are currently underway. Subsequent to these findings, it has been demonstrated that lithium also increases bcl-2 levels in C57BL/6 mice, 146 in neuroblastoma SH-SY5Y cells (human neuronal origin) in vitro, 151 and in rat cerebellar granule cells in vitro. 152 The latter study was undertaken as part of investigations into the molecular and cellular mechanisms underlying the neuroprotective actions of lithium against glutamate excitotoxicity (see below). These investigators found that lithium produced a remarkable increase in bcl-2 protein and mRNA levels. Moreover, lithium has recently been demonstrated to reduce the levels of the proapoptotic protein p53 both in cerebellar granule cells 152 and in neuroblastoma SH-SY5Y cells. 153 Thus, overall, the data clearly show that chronic lithium robustly increases the levels of the neuroprotective protein bcl-2 in areas of rodent FC, hippocampus, and striatum in vivo, and in cultured cells of both rodent and human neuronal origin in vitro. Furthermore, at least in cultured cell systems, lithium has also been demonstrated to reduce the levels of the proapoptotic protein p53. Consistent with bcl-2's known cytoprotective effects, lithium, at therapeutically relevant concentrations, has been shown to exert neuroprotective effects in a variety of preclinical paradigms. Thus, lithium has been demonstrated to protect against the deleterious effects of glutamate, NMDA receptor activation, aging, serum/NGF deprivation, ouabain, thapsigargin (which mobilizes intracellular methlphenylpyridinium (MPP + ), Ca 2+ ), and β-amyloid in vitro. 149 More importantly, lithium's neurotrophic and cytoprotective effects have also been demonstrated in rodent brain in vivo. Thus, lithium treatment has been shown to attenuate the biochemical deficits produced by kainic acid infusion, ibotenic acid infusion, and forebrain cholinergic system lesions, 149, 154, 155 to exert dramatic protective effects against middle cerebral artery occlusion, 156 and to enhance hippocampal neurogenesis in the adult rodent hippocampus. 157 The potential therapeutic relevance of these preclinical findings in discussed below.
Human evidence for the neurotrophic effects of mood stabilizers
While the body of preclinical data demonstrating neurotrophic and neuroprotective effects of lithium is striking, considerable caution must clearly be exercised in extrapolating to the clinical situation with humans. In view of lithium and VPA's robust effects on the levels of the cytoprotective protein bcl-2 in the FC, Drevets and associates 28 reanalyzed older data demonstrating approximately 40% reductions in subgenual PFC volumes in familial mood disorder subjects. Consistent with neurotrophic/neuroprotective effects of lithium and VPA, they found that the patients treated with chronic lithium or VPA exhibited subgenual PFC volumes, which were significantly higher than the volumes in non-lithiumtreated or VPA-treated patients, and not significantly different from controls. 158 Although the results of the study by Drevets 158 suggest that mood stabilizers may have provided neuroprotective effects during naturalistic use, considerable caution is warranted in view of the small sample size and crosssectional nature of the study. To investigate the potential neurotrophic effects of lithium in humans more definitively, a longitudinal clinical study was recently undertaken using proton magnetic resonance spectroscopy (MRS) to quantify N-acetylaspartate (NAA, a putative marker of neuronal viability) levels. It was found that chronic lithium administration at therapeutic doses increases NAA concentration in the human brain in vivo. 159 These findings provide intriguing indirect support for the contention that, similar to the findings observed in the rodent brain and in human neuronal cells in culture, chronic lithium increases neuronal viability/function in the human brain. Furthermore, a striking approximately 0.97 correlation between lithiuminduced NAA increases and regional voxel gray matter content was observed, 159 thereby providing evidence for colocalization with the region-specific bcl-2 increases observed in the rodent brain cortices (eg, gray versus white matter). These results suggest that chronic lithium may exert not only robust neuroprotective effects (as has been demonstrated in a variety of preclinical paradigms), but also neurotrophic effects in humans. In follow-up studies to the NAA findings, it was hypothesized that, in addition to increasing functional neurochemical markers of neuronal viability, lithium-induced increases in bcl-2 would also lead to neuropil increases, C l i n i c a l r e s e a r c h and thus to increased brain gray matter volume in patients with bipolar disorder. In this clinical research investigation, 130 brain tissue volumes were examined using high-resolution three-dimensional MRI and validated quantitative brain tissue segmentation methodology to identify and quantify the various components by volume, including total brain white and gray matter content. Measurements were made at baseline (medicationfree, after a minimum 14-day washout) and then repeated after 4 weeks of lithium at therapeutic doses. This study revealed that chronic lithium significantly increases total gray matter content in the human brain of patients with bipolar disorder (Figure 2) . 130 No significant changes were observed in brain white matter volume or in quantitative measures of regional cerebral water content, thereby providing strong evidence that the observed volumes using high-resolution three-dimensional magnetic resonance imaging (MRI) (124 images, 1.5-mm thick coronal T 1 weighted spoiled gradient (SPGR) images), and validated quantitative brain tissue segmentation methodology to identify and quantify the various components by volume, including total brain white and gray matter content. Measurements were made at baseline (medication-free, after a minimum 14-day washout) and then repeated after 4 weeks of lithium at therapeutic doses. Chronic lithium significantly increases total gray matter content in the human brain of patients with bipolar disorder. No significant changes were observed in white matter volume, or in quantitative measures of regional cerebral water.
increases in gray matter content are likely due to neurotrophic effects as opposed to any possible cell swelling and/or osmotic effects associated with lithium treatment. A finer-grained subregional analysis of this brain imaging data is ongoing, and suggests that lithium produces a regionally selective increase in gray matter, with prominent effects being observed in hippocampus and caudate (unpublished observations).
Concluding remarks: implications for development of new medications
As discussed, there is a considerable body of evidence both conceptually and experimentally in support of the regulation of signaling cascades regulating synaptic plasticity and cellular resilience in the treatment (and potentially pathophysiology) of mood disorders. Regulation of signal transduction within critical regions of the brain affects the intracellular signal generated by multiple neurotransmitter systems; these effects thus represent attractive putative mediators of the pathophysiology of mood disorders and the therapeutic actions of antidepressants and mood stabilizers. It is also becoming increasingly clear that, for many refractory mood disorder patients, new drugs that simply mimic many "traditional" drugs, which directly or indirectly alter neurotransmitter levels, and those which bind to cell surface receptors may be of limited benefit. This is because such strategies implicitly assume that the target receptor(s)-and downstream signal mediators-are functionally intact, and that altered synaptic activity will thus be transduced to modify the postsynaptic "throughput" of the system. However, the possible existence of abnormalities in signal transduction pathways suggests that, for patients refractory to conventional medications, improved therapeutics may only be obtained by the direct targeting of postreceptor sites. Recent discoveries concerning a variety of mechanisms involved in the formation and inactivation of second messengers offers the promise for the development of novel pharmacological agents designed to target signal transduction pathways. Although clearly more complex than the development of receptor-specific drugs, it may be possible to design novel agents to selectively affect second messenger systems, because they are quite heterogeneous at the molecular and cellular level, are linked to receptors in a variety of ways, and are expressed in different stoichiometries in different cell types. Additionally, since signal transduction pathways display certain unique characteristics depending on their activity state, they offer built-in targets for relative specificity of action, depending on the "setpoint" of the substrate. It is also noteworthy that a variety of strategies to enhance neurotrophic factor signaling are currently under investigation. An increasing number of strategies are being investigated to develop small molecular switches for protein-protein interactions, which have the potential to regulate the activity of growth factors, MAP kinase cascades, and interactions between homo-and heterodimers of the bcl-2 family of proteins 160 ; this progress holds much promise for the development of novel therapeutics agents for the long-term treatment of severe mood disorders, and for improving the lives of millions. ❑ C l i n i c a l r e s e a r c h 88 El aumento de la plasticidad sináptica y de la resiliencia celular como medio para desarrollar originales y mejores terapias para los trastornos del ánimo 
